Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: A possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings

Clinical Oral Investigations

Volumn 14, Issue 3, 2010, Pages 271-284

  Hoefert, Sebastian ^a   Schmitz, Inge ^b   Tannapfel, Andrea ^b   Eufinger, Harald ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Bisphosphonates; Jawbone; Microcracks; Osteonecrosis of the jaw; Scanning electron microscopy

Indexed keywords

EID: 77952428207     PISSN: 14326981     EISSN: 14363771     Source Type: Journal    
DOI: 10.1007/s00784-009-0300-6     Document Type: Article

References (57)

1. Abu-Id MH, Acil Y, Gottschalk J, Kreusch T (2006) Bisphosphonatassoziierte Osteonekrose des Kiefers. Mund Kiefer Gesichtschir 10: 73-81.
2. Allen MR, Burr DB (2008) Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66: 987-994.
3. Altundal H, Guevener OE (2004) The effect of alendronate on resorption of the alveolar bone following tooth extraction. Int J Oral Maxillofac Surg 33: 286-293.
4. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T (2006) Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24: 945-952.
5. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Papadimitriou C, Terpos E, Dimopoulos A (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23: 8580-8587.
6. Bouvier M, Hylander WL (1981) Effect of bone strain on cortical bone structure in macaques (Macaca mulatta). J Morph 167: 1-12.
7. Bras J, de Jonge HKT, van Merkensteyn JPR (1990) Osteoradionecrosis of the mandible: pathogenesis. Am J Otolaryngol 11: 244-250.
8. Bukowski JF, Dascher CC, Das H (2005) Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 328: 746-750.
9. Burr DB, Hooser M (1995) Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. Bone 17: 431-433.
10. Burr DB, Stafford T (1990) Validity of the bulk staining technique to separate artificial from in vivo bone microdamage. Clin Orthop Relat Res 260: 305-308.
11. Burr DB, Martin RB, Schaffler MB, Radin EL (1985) Bone remodeling in response to in vivo fatigue microdamage. J Biomech 18: 189-200.
12. Conti L, Casetti R, Cardone M, Varano B, Martino A, Belardelli F, Poccia F, Gessani S (2005) Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines. J Immunol 174: 252-260.
13. Day JS, Ding M, Bednarz P, van der Linden JC, Mashiba T, Hirano T, Johnston CC, Burr DB, Hvid I, Sumner DR, Weinans H (2004) Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res 22: 465-471.
14. Dechow PC, Hylander WL (2000) Elastic properties and masticatory bone stress in the macaque mandible. Am J Phys Anthropol 112: 553-574.
15. Dicuonzo G, Vincenzi B, Santini D, Avvisati L, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G (2003) Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res 23: 649-654.
16. Dieli F, Gebbia N, Poccia F, Gaccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A (2003) Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102: 2310-2311.
17. Enzendam J, Kosterman K, Spijkerboer H, Bleumink R, Hassing I, van Rooijen N, Vos JG, Pieters R (2005) Macrophages are involved in hexachlorobenzene-induced adverse effects. Toxicol Appl Pharmacol 209: 19-27.
18. Frost HM (1960) Presence of microscopic cracks in vivo in bone. Henry Ford Hosp Med Bull 8: 25-35.
19. Hansen T, Kunkel M, Kirkpatrick CJ, Weber A (2006) Actimomyces in infected osteoradionecrosis-underestimated? Human Pathol 37: 61-67.
20. Hansen T, Kunkel M, Weber A, Kirkpatrick CJ (2006) Osteonecrosis of the jaws in patients treated with bisphosphonates-histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35: 155-160.
21. Hansen T, Wagner W, Kirkpatrick CJ, Kunkel M (2006) Infected osteoradionecrosis of the mandible: follow-up study suggests deterioration in outcome for patients with actinomyces-positive bone biopsies. Int J Oral Maxillofac Surg 35: 1001-1004.
22. Hellstein JW, Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63: 682-689.
23. Hess LM, Jeter NJ, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121: 475-483.
24. Hewitt RE, Lissina A, Green AE, Slay ES, Price DA, Sewell AK (2005) The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobishosphonates is inhibited by statins. Clin Exp Immunol 139: 101-111.
25. Hoefert S, Eufinger H (2006) Nekrosen der Kieferknochen unter Bisphosphonattherapie. Orthopäde 35: 204-209.
26. Hoefert S, Wierich W, Eufinger H, Krempien B (2006) BP-associated avascular necrosis (AN) of the jaws: histological findings. Bone 38(Suppl): 76.
27. Hu JH, Ding M, Soballe K, Bechtold JE, Danielsen CC, Days JS, Hvid I (2002) Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone. Bone 31: 591-597.
28. Huja SS, Hasan MS, Pidaparti R, Turner CH, Garetto LP, Burr DB (1999) Development of a fluorescent light technique for evaluating microdamage in bone subjected to fatigue loading. J Biomech 32: 1243-1249.
29. Huk OL, Zukor DJ, Antoniou J, Petit A (2003) Effect of pamidronate on the stimulation of macrophage TNF-alpha release by ultra-high-molecular-weight polyethylene particles: a role for apoptosis. J Orthop Res 21: 81-87.
30. Jereczek-Fossa BA, Orechia R (2002) Radiotherapy-induced mandibular bone complications. Cancer Treat Rev 28: 65-74.
31. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Lillian Shum L, Silverman SL, van Poznak CH, Watts N, Woo SB, Shane E (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of the task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479-1491.
32. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha LA, Raghavan S (2008) Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 66: 839-847.
33. Lee TC, Mohsin S, Taylor D, Parkesh R, Gunnlaugsson T, O'Brien FJ, Giehl M, Gowin W (2003) Detecting microdamage in bone. J Anat 203: 161-172.
34. Leemans JC, Juffermans NP, Florquin S, van Rooijen N, Vervoordeldank MJ, Verbon A, Deventer SJH, van der Poll T (2001) Depletion of alveolar macrophages exerts protective effects in pulmonary tuberculosis in mice. J Immunol 166: 4604-4611.
35. Li J, Mashiba T, Burr DB (2001) Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Cacif Tissue Int 69: 281-286.
36. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 1115-1118.
37. Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575.
38. Mendenhall WM (2004) Mandibular osteoradionecrosis. J Clin Oncol 22: 4867-4868.
39. Migliorati CA (2003) Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21: 253-254.
40. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Sook-Bin MS (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis. An American academy of oral medicine position paper. JADA 136: 1658-1668.
41. Moreau MF, Guillet C, Massin P, Chavalier S, Gascan H, Basle MF, Chapparad D (2007) Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 73: 718-723.
42. O'Brien FJ, Brennan O, Kennedy OD, Lee C (2005) Microcracks in cortical bone: how do they affect bone biology? Curr Osteoporos Rep 3: 39-45.
43. Odvina CV, Zerwkh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294-1301.
44. Ott SM (2005) Editoral: long-term safety of bisphosphonates. J Clin Endocrinol Metab 90: 1897-1899.
45. Papapoulos SE (2001) Catabolic and anabolic signals in bone: therapeutic implications. Curr Opin Clin Nutr Metab Care 4: 191-196.
46. Peleg M, Lopez EAL (2006) The treatment of osteoradionecrosis of the mandible: the case for hyperbaric oxygen and bone graft reconstruction. J Oral Maxillofac Surg 64: 956-960.
47. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphophonates and calcitonin. J Clin Invest 104: 1363-1374.
48. Reid IR, Bolland MJ, Grey AB (2007) Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 47: 318-320.
49. Rizzoli R, Burlet N, Cahall D, Delmas PD, Eriksen EF, Felsenberg D, Grbic J, Jontell M, Landesberg R, Laslop A, Wollenhaupt M, Papapoulos S, Sezer O, Sprafka M, Reginster JY (2008) Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42: 841-847.
50. Ruggiero SL, Mehrotra B, Rosenberg T, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527-534.
51. Ruggiero SL, Fantasia J, Carlson E (2006) Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 433-441.
52. Sarin J, DeRossi SS, Akintoye SO (2008) Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 14: 277-285.
53. Schaffler MB, Pitchford K, Choi K, Riddle M (1994) Examination of compact bone microdamage using back-scattered electron microscopy. Bone 15: 483-488.
54. Sedghizadeh PP, Kumar SKS, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2008) Identification of microbiofilms in osteonecrosis of the jaws secondary to bisphosphonte therapy. J Oral Maxillofac Surg 66: 767-775.
55. Takagi K, Takagi M, Kanangat S, Warrington KJ, Shigemitsu H, Postlethwaite AE (2005) Modulation of TNF-alpha gene expression by IFN-gamma and pamidronate in murine macrophages: regulation by STAT1-dependent pathways. J Immunol 174: 1801-1810.
56. van Poznak C (2006) The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer. Cancer Invest 24: 110-112.
57. Wannfors K, Hammarström L (1985) Infectious foci in chronic osteomyelitis of the jaws. Int J Oral Surg 14: 493-503.